Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community

Affiliations

Comment

Richard Cunningham. CMAJ. 2006.

. 2006 Sep 26;175(7):757.

doi: 10.1503/cmaj.060919.

No abstract available

Comment on

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
Dial S, Delaney JA, Schneider V, Suissa S. Dial S, et al. CMAJ. 2006 Sep 26;175(7):745-8. doi: 10.1503/cmaj.060284. CMAJ. 2006. PMID: 17001054 Free PMC article.

1. Archibald LK, Banerjee SH, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 2004;189:1585-9. - PubMed
1. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-72. - PMC - PubMed
1. Health Protection Agency. Reports of Clostridium difficile isolated from faecal specimens under the voluntary reporting scheme: England, Wales, and Northern Ireland 1990–2004. London: The Agency. Available: www.hpa.org.uk/infections/topics_az/clostridium_difficile/vol_data.htm (accessed 2006 Aug 17).
1. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9. - PubMed
1. Pépin J, Saheb N, Coulombe M, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60. - PubMed